We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Disentangling Fear and Hypoglycemia Metrics in Type 1 Diabetes: Insights from a 12-Month Diabetes Technology Study

MedXY Editorial Team•Sep 9, 2026•Diabetes & Endocrinology
type 1 diabetescontinuous glucose monitoringDiabetes Technology

An infographic summarises a study of fear and perception of hypoglycemia in adults with type 1 diabetes using glucose monitoring technology. Data come from 254 adults using real-time continuous glucose monitoring and 1,116 adults using hybrid closed-loop systems. Changes from technology start to 12 months are analyzed. Scatter plots of change in hypoglycemia fear or perception against change in time below 3.9 millimoles per liter show random distributions. Findings state no significant correlation between hypoglycemia fear, hypoglycemia perception, and glucose monitoring metrics.

Highlight

  • Fear and perceived frequency of hypoglycemia decreased over 12 months of technology use despite modest changes in hypoglycemia CGM metrics.
  • No clear correlations were found between hypoglycemia fear scales and CGM metrics at baseline, 12 months, or their longitudinal changes.
  • Findings suggest that psychological factors influencing hypoglycemia fear extend beyond actual glucose data gathered from continuous glucose monitoring.
  • Integration of psychosocial assessment remains critical alongside glycemic monitoring in type 1 diabetes management.

Study Background

Type 1 diabetes mellitus (T1DM) necessitates vigilant glycemic control to prevent both hyperglycemia and hypoglycemia. Hypoglycemia, defined as low blood glucose levels, is a common and potentially dangerous complication, frequently inducing significant fear and anxiety in patients. This fear can deteriorate quality of life and impact diabetes self-management behaviors. Despite advancement in diabetes technologies such as continuous glucose monitoring (CGM) and hybrid closed-loop insulin delivery systems, understanding the interplay between patients’ psychological responses—especially fear of hypoglycemia—and objective glucose metrics remains an unmet clinical need. Clarifying this relationship can inform holistic care strategies that integrate glycemic control with psychosocial well-being in adults with T1DM.

Study Design

This retrospective exploratory study analyzed data from 1,370 adults with type 1 diabetes over 12 months, derived from two prospective trials: ALERTT1 (n=254), using real-time CGM, and INRANGE (n=1,116), employing hybrid closed-loop insulin delivery systems. Participants had a mean age of 41 years with longstanding diabetes (mean duration 21.6 years). Key measures included continuous CGM metrics of glucose exposure and variability—specifically time spent below hypoglycemia thresholds (<3.9 and <3.0 mmol/L)—and validated self-reported scales assessing fear and perceived frequency of hypoglycemia. These psychological endpoints were the Hypoglycemia Fear Survey II worry (HFS-worry) and behavior (HFS-behavior) subscales and the Diabetes Treatment Satisfaction Questionnaire-status hypoglycemia subscale (DTSQs-hypo). Baseline, 12-month, and longitudinal changes in these variables were statistically analyzed for associations.

Key Findings

At baseline, participants demonstrated a mean HbA1c of 7.6% (59 mmol/mol) and spent on average 3.4% and 0.8% of their time below 3.9 mmol/L and 3.0 mmol/L glucose thresholds respectively. Over the 12-month period, time in hypoglycemia significantly decreased (from 3.4% to 2.3% for <3.9 mmol/L, and from 0.8% to 0.5% for <3.0 mmol/L). Concomitantly, mean scores on HFS-worry (from 21.0 to 16.8) and DTSQs-hypo (from 3.3 to 2.7) also decreased, indicating reduced fear and perceived hypoglycemia frequency.

Despite these parallel trends, correlation analyses revealed no clear or consistent associations between fear or perceived hypoglycemia scores and CGM-derived hypoglycemia metrics at baseline, after 12 months, or for the 12-month changes. Similarly, no significant correlations were observed with other CGM metrics such as time in range or hyperglycemia exposure. The behavioral subscale of the HFS also failed to show meaningful linkage with objective glucose data.

This dissociation suggests that individuals’ subjective experience and fear of hypoglycemia do not depend solely on the amount or severity of hypoglycemic episodes detected by technology. Other psychological, social, or experiential factors likely modulate these perceptions and behaviors.

Expert Commentary

This comprehensive study contributes valuable insights into the complexity of hypoglycemia-related fear in longstanding T1DM managed with modern diabetes technologies. The data reinforce that reduction in hypoglycemia exposure, achievable through CGM and hybrid closed-loop systems, does not directly translate to proportional reductions in hypoglycemia fear. This underscores the multidimensional nature of fear, which may relate to previous severe episodes, hypoglycemia awareness, psychosocial stressors, or individual psychological traits.

The lack of correlation aligns with previous literature emphasizing the limited predictive value of glucose metrics alone for hypoglycemia fear (Patton et al., 2019; Gonder-Frederick et al., 2011). Clinical management should therefore incorporate routine psychosocial screening and interventions such as cognitive behavioral therapy targeted at hypoglycemia-related anxiety.

Limitations include the retrospective nature of this secondary analysis and potential selection bias from the parent trials. Nonetheless, the large sample size and multi-technology use enhance generalizability. Future research might investigate dynamic and real-time assessment of fear alongside CGM data to elucidate causal temporal patterns.

Conclusion

This 12-month analysis in adults with type 1 diabetes using real-time CGM and hybrid closed-loop technology demonstrates that while hypoglycemia exposure and fear both decline, their trajectories do not correlate directly. Fear and perceived frequency of hypoglycemia are influenced by additional factors beyond glycemic profiles alone. These findings highlight the necessity for integrative diabetes care approaches that combine technological advances in glucose monitoring with individualized psychological support to optimize patient well-being and treatment satisfaction.

Funding and clinicaltrials.gov

The study was supported by institutional research funding from the involved academic clinics and diabetes technology grants. ClinicalTrials.gov identifiers for the parent trials are NCT03642555 (ALERTT1) and NCT03991130 (INRANGE).

References

1. Patton SR, et al. Association Between Hypoglycemia Fear and Glucose Control in Youth With Type 1 Diabetes Using Real-Time Continuous Glucose Monitoring. Diabetes Technol Ther. 2019;21(6):300-307.
2. Gonder-Frederick L, et al. Psychological aspects of hypoglycemia in diabetes. Diabetes Spectrum. 2011;24(1):41-46.
3. Valgaerts L, et al. The Correlation Between Fear and Perceived Frequency of Hypoglycemia and Continuous Glucose Monitoring Metrics in Adults With Type 1 Diabetes Using Diabetes Technology: A 1-Year Analysis. Diabetes Care. 2026 Sep 1;49(9):1637-1644. doi: 10.2337/dc26-0118.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Advancing SGLT Inhibitor Use for Heart and Kidney Protection in Type 1 Diabetes: Opportunities and ChallengesThis article reviews expert perspectives on the efficacy and safety of SGLT inhibitors for cardiovascular and renal disease in type 1 diabetes, outlines translational insights from type 2 diabetes data, and proposes a roadmap for regulatorySep 15, 2026β-Cell Dysfunction Enhances Prediction of Type 1 Diabetes Progression in Individuals with Single Autoantibody PositivityAssessment of β-cell dysfunction using stimulated glucose and C-peptide measures improves risk stratification for type 1 diabetes progression among single autoantibody-positive relatives, enabling personalized monitoring and targeted intervSep 15, 2026New International Consensus: Screening the General Population for Islet Autoantibodies to Detect Early-Stage Type 1 DiabetesAn international expert consensus recommends practical principles and minimum requirements for general‑population screening for islet autoantibodies to detect early-stage type 1 diabetes, reduce DKA, enable early care and access to disease‑Sep 13, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing &amp; care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Teplizumab Preserves Beta Cell Function in Youth with Newly Diagnosed Type 1 Diabetes: Insights from the PROTECT Trial Per-Protocol Analysis
The PROTECT trial&#8217;s per-protocol analysis confirms teplizumab&#8217;s efficacy in preserving beta cell function, reducing insulin needs, and improving glycemic control in children and adolescents newly diagnosed with stage 3 type 1 di
Sep 13, 2026
Continuous Glucose Monitoring Using the FreeStyle Libre Pro iQ in Presymptomatic Type 1 Diabetes: Advancements in Early Detection and Risk StratificationThis review examines the role of FreeStyle Libre Pro iQ CGM in differentiating presymptomatic stages of type 1 diabetes and predicting progression to clinical disease, comparing its performance with Dexcom G6 and discussing implications forSep 12, 2026
Rising Incidence of Islet Autoimmunity Among Colorado Children With Moderate-Risk HLA Genotypes: Insights From Longitudinal CohortsA study reveals a significant secular increase in islet autoimmunity incidence among Colorado children from 1993 to 2010, particularly in those with moderate-risk HLA genotypes, highlighting evolving risk profiles beyond known environmentalSep 11, 2026